코아스템켐온

166480KOSDAQ

43.0 / 100

Reference Date: 2026-10-23

Financial Score13.5 / 40

News Sentiment12.5 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 21.4% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

CoaStemKemOn focuses on developing and selling stem cell therapies, with its product 'NeuroNata-Al' for Lou Gehrig's disease commercialized since 2015. The company merged with KemOn, a top non-clinical CRO firm in South Korea, in 2022 to enhance R&D capabilities, and approximately 98% of its revenue comes from non-clinical research services.

Number of Employees

321people

Average Salary

48.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

1.61Industry Average 1.202.5Point

Higher than industry avg (caution)

ROE

-51.72Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

36.21Industry Average 100.006.5Point

Half of industry avg (excellent)

Trend 2023~20250.5 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼22.2% (2-year basis)

Operating Profit Growth Rate

0.5 / 3

Avg ▼4.1% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -63.1% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (16%, downtrend)

Current 1,682Won52-week high 4,80052-week low 1,060

1-month return0.0Point

1m -21.40% (strong drop)

Volume trend6.0Point

Volume increasing

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0